Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Experimental cancer drug tested in early trial, but study stopped early

NCT ID NCT06466187

Disease control Sponsor: Seagen, a wholly owned subsidiary of Pfizer Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 08, 2026 · Updated 2 times

Summary

This early-stage trial tested an experimental drug called PF-08052666 in 19 people with advanced solid tumors like lung, ovarian, and pancreatic cancers that had not responded to standard treatments. The drug is designed to target and kill cancer cells. The study aimed to find a safe dose and check for side effects, but it was terminated early, so full results are not available.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
PF-08052666 (also called SGN-MesoC2), an antibody-drug conjugate given into the vein
What this could lead to
If it works, this could point toward a new treatment option for certain advanced solid tumors that have not responded to standard therapies.
What could go wrong
This is a very early Phase 1 trial that was terminated early, so results are limited. The drug may not prove effective or safe in larger studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

19 people

The number who actually took part.

Started

Aug 2024

Finished

May 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Aged 18 years or older. * Histologically- or cytologically-confirmed metastatic or locally advanced unresectable platinum-resistant ovarian cancer, NSCLC, pancreatic ductal adenocarcinoma, endometrial cancer, colorectal cancer, or mesothelioma, who have relapsed or progressed following standard therapies, or for which no standard therapies are available. * An Eastern Cooperative Oncology Group performance status score of 0 or 1. * At least 1 measurable lesion at baseline based on Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1). * Archival tumor tissue or a fresh tumor biopsy during the screening period. * Adequate hepatic, renal and bone marrow function. * Participants must not have received more than 2 lines of cytotoxic systemic therapy in the metastatic setting (Parts B and C only). Exclusion Criteria: * Previously received or currently receiving any systemic anticancer therapy or focal radiotherapy within 4 weeks prior to the first dose of MesoC2 or within 2 weeks prior to the first dose of MesoC2 if the underlying disease had progressed on treatment. * Prior anti-MSLN antibody or MSLN-directed ADC (Part C only). * Unresolved toxicities from prior therapy greater than NCI CTCAE v5.0 grade 1 at the time of study treatment (except alopecia). * Inadequate hepatic dysfunction, renal function, or hematologic abnormalities. * Previously untreated brain metastases. Participants who received radiation or surgery for brain metastases are eligible if therapy was completed at least 4 weeks prior to study treatment initiation, and there was no evidence of central nervous system progression nor requirements for chronic corticosteroid therapy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Carcinoma, non-small-cell lung are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

colorectal cancer colorectal neoplasm endometrial cancer endometrium neoplasm lung neoplasm mesothelioma neoplasm non-small cell lung carcinoma ovarian cancer ovarian neoplasm pancreatic adenocarcinoma pancreatic ductal adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Carcinoma, non-small-cell lung Colorectal neoplasms Endometrial Mesothelioma Other solid tumors Ovarian neoplasms Pancreatic adenocarcinoma

Contacts and locations

Locations

  • Atrium Health Wake Forest Baptist

    Winston-Salem, North Carolina, 27157, United States

  • McGill University Health Centre

    Montreal, Quebec, H4A 3J1, Canada

  • SCRI Oncology Partners

    Nashville, Tennessee, 37203, United States

  • START Mountain Region, LLC

    West Valley City, Utah, 84119, United States

  • START San Antonio, LLC

    San Antonio, Texas, 78229, United States

  • Sarah Cannon Research Institute - Pharmacy

    Nashville, Tennessee, 37203, United States

  • The Board of Trustees of the University of Alabama for the University of Alabama at Birmingham

    Birmingham, Alabama, 35294, United States

  • The University of Alabama at Birmingham

    Birmingham, Alabama, 35249, United States

  • The University of Kansas Cancer Center - Indian Creek Campus

    Overland Park, Kansas, 66211, United States

  • The University of Kansas Cancer Center - Westwood

    Westwood, Kansas, 66205, United States

  • The University of Kansas Cancer Center, Investigational Drug Services

    Westwood, Kansas, 66205, United States

  • The University of Kansas Clinical Research Center

    Fairway, Kansas, 66205, United States

  • The University of Kansas Hospital

    Kansas City, Kansas, 66160, United States

  • The University of Kansas Hospital Cambridge North Tower A

    Kansas City, Kansas, 66160, United States

  • The University of Kansas Medical Center Medical Office Building

    Kansas City, Kansas, 66160, United States

  • University Health Network

    Toronto, Ontario, M5G 2C4, Canada

  • University Health Network, Princess Margaret Cancer Centre

    Toronto, Ontario, M5G 2M9, Canada

  • University of Alabama at Birmingham

    Birmingham, Alabama, 35233, United States

  • University of Alabama at Birmingham

    Birmingham, Alabama, 35249, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.